Back to today’s briefing

Story perspectives

FDA Warns ImmunityBio Over Misleading Cancer Claims, Stock Drops 24%

3/25/2026

34 2 Full Breakdown

Summary

Story summary

The U.S. Food and Drug Administration issued the first 2026 warning letter to ImmunityBio for misleading promotional statements about Anktiva.
The FDA criticized a TV ad and podcast featuring ImmunityBio executives for falsely claiming Anktiva treats all cancers.
The agency noted Anktiva is approved only for bladder cancer.
ImmunityBio's stock fell 24% after the letter.

1 of 1

Story summary

The U.S. Food and Drug Administration issued the first 2026 warning letter to ImmunityBio for misleading promotional statements about Anktiva.
The FDA criticized a TV ad and podcast featuring ImmunityBio executives for falsely claiming Anktiva treats all cancers.
The agency noted Anktiva is approved only for bladder cancer.
ImmunityBio's stock fell 24% after the letter.